Use of ibezapolstat to promote microbiome health

Inventors

GAREY, Kevin

Assignees

Acurx Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12036225-B2

Patent

Publication Date

2024-07-16

Expiration Date


Abstract

The invention relates to methods of using ibezapolstat to increase the health of the gut microbiome. The invention provides methods of simultaneously treating C. difficile infections while at the same time reducing the likelihood of or preventing the recurrence of C. difficile infection. The invention also provides methods of increasing the health of the gut microbiome by increasing the number of Actinobacteria and/or Firmicutes in the gut.

Core Innovation

The disclosed invention relates to ibezapolstat as a DNA polymerase IIIC inhibitor for treating C. difficile infection in a human subject. The method comprises administering at least about 300 mg to about 1000 mg of ibezapolstat, where the administration simultaneously treats the C. difficile infection and reduces the likelihood of or prevents the recurrence of CDI within 90 days.

The invention further characterizes microbiome effects associated with ibezapolstat administration. The method is described as selectively targeting Firmicutes in the gut microbiome, and as resulting in a change and reduction in the proportion of Firmicutes to Proteobacteria, together with microbiome shifts described as increased Actinobacteria and/or Firmicutes and a shift away from Proteobacteria bloom.

Mechanistic rationale and observations are described in terms of selective activity against low G+C Gram-positive bacteria, including Firmicutes and C. difficile, while sparing Actinobacteria and Bacteroidetes. The document summarizes microbiome and bile acid outcomes, including reduced disruption of alpha diversity versus vancomycin and distinct microbiome profiles and bile acid metrics.

Claims Coverage

The partial content includes three independent claims. Across these independent claims, the coverage centers on ibezapolstat dosing (about 300 mg to about 1000 mg), reduction or prevention of CDI recurrence within 90 days, and distinct microbiome-directed features including selective targeting of Firmicutes and a reduction or change in the Firmicutes-to-Proteobacteria proportion.

Simultaneous CDI treatment with 90-day recurrence prevention

Administering at least about 300 mg to about 1000 mg of ibezapolstat to a human subject suffering from a C. difficile infection, wherein the administration simultaneously treats the C. difficile infection and reduces the likelihood or prevents recurrence within 90 days.

CDI treatment with selective Firmicutes targeting in the gut microbiome

Administering at least about 300 mg to about 1000 mg of ibezapolstat to a human subject suffering from a C. difficile infection, wherein the administration reduces recurrence of C. difficile infection within 90 days and selectively targets Firmicutes in the gut microbiome of the subject.

Microbiome proportion change in Firmicutes to Proteobacteria

Administering at least about 300 mg to about 1000 mg of ibezapolstat to a subject, wherein the administration results in a change and reduction in the proportion of Firmicutes to Proteobacteria in a gut microbiome, wherein the subject is suffering from a C. difficile infection or is susceptible to a recurrence, and wherein the administration prevents recurrence within 90 days.

Across the independent claims, ibezapolstat is required for reducing recurrence of CDI within 90 days while also tying the treatment to microbiome-directed features, including simultaneous CDI treatment, selective targeting of Firmicutes, and a reduction or change in the Firmicutes-to-Proteobacteria proportion in the gut microbiome.

Stated Advantages

Simultaneously treats C. difficile infection and reduces the likelihood of or prevents recurrence within 90 days.

Reduces the likelihood of or prevents recurrence of C. difficile infection within 90 days.

Selectively targets Firmicutes in the gut microbiome.

Changes and reduces the proportion of Firmicutes to Proteobacteria in a gut microbiome to prevent recurrence.

Reduces disruption of alpha diversity versus vancomycin.

Produces a distinct microbiome profile versus vancomycin, including avoiding vancomycin-associated Proteobacteria increase.

Produces bile acid outcomes described as less extreme primary and secondary bile acid disruption compared to vancomycin.

Phase 2a results are described as 100% clinical cure and sustained cure during and after therapy with favorable microbiome and bile acid metrics.

Documented Applications

Treating C. difficile infection in a human subject, including simultaneously treating the infection and reducing likelihood of recurrence within 90 days.

Reducing the likelihood of C. difficile infection and preventing recurrence in a human subject who is suffering from CDI or is susceptible to recurrence.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.